Synthesis of a Hydroxy-15-Azasterol.

Caleb A H Jones, Bruce J Melancon, Craig W Lindsley

Abstract read

In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Caleb A H JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-0471-9392

Bruce J MelanconWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.

Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0003-0168-1445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Niemann-Pick type C (NPC) is a lysosomal storage disorder that will cause eventual brain damage with limited treatment options available. Though clinical trials are undergoing with repurposed pharmaceuticals, no novel chemotype exists purely for the treatment of NPC. In 2021, an azasterol was found to bind to both NPC1 and NPC2 proteins and is considered as a cholesterol mimic. A convergent synthesis to obtain a hydroxy-15-azasterol was completed in 12 steps, from 2-oxepanone.

Identifiers

PMID39959107

DOI10.1021/acsomega.4c09907

PMCPMC11822486

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.